Virbac Unveils Canine Cephalexin Tablet

Posted: Sept. 5, 2012, 8:05 p.m. EDT



Published:

Virbac Animal Health of Fort Worth, Texas, launched the first chewable cephalexin tablet designed exclusively for dogs, the company reported Tuesday.

The FDA-approved drug, called Rilexine, is indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Previously, veterinarians often relied on the generic human form of cephalexin to treat dogs, but Rilexine is the first drug of its kind approved by the U.S. Food and Drug administration for the veterinary market, Virbac reported. The new drug should overcome some of the drawbacks of prescribing human cephalexin off-label, including a bitter, metallic taste and strong odor, a lack of veterinary-specific guidelines and the inability to tailor doses, Virbac noted.

Pyoderma is one of the most common diseases seen in dogs, and secondary superficial bacterial pyoderma is the most common form of pyoderma, according to Virbac.

Rilexine is available in 150 mg, 300 mg and 600 mg scored doses. The drug should not be prescribed to dogs that have a known allergy to cephalexin or the B-lactam group of antibiotics.

<HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

Study May Lead to Early Diagnosis of Feline Kidney Disease

The biomarker SDMA identified the onset of kidney disease an average of 17 months earlier in cats and in one case four years earlier.

Merck Launches Overseas Veterinarian Exchange

The Nobivac Global Vet Exchange Program allows practitioners to observe how veterinary medicine is performed in other countries.

Petco Buying Drs. Foster and Smith

Co-founders Race Foster and Marty Smith will stay with Drs. Foster and Smith when Petco takes ownership and branches into drug sales in early 2015.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module